Omega Therapeutics, Inc.

Based in Massachusetts, US, and founded in 2017 by co-founders Noubar Afeyan and David Berry, Omega Therapeutics, Inc. is a development-stage biotechnology company. Mahesh Karande is the current President and CEO of the company. The company as of 2021 has eight programs in various stages of preclinical development.

The company raised its first funding in July 2020, followed by another funding in March 2021. Omega Therapeutics filed confidentially in May 2021 to become a public company. In July 2021, the business conducted in vivo preclinical research in hepatocellular carcinoma, non-small cell lung cancer, and acute respiratory distress syndrome. Omega Therapeutics is a genomic medicine enterprise that is developing innovative engineered therapeutics, Omega's Epigenomic Regulators, into clinical development for a wide variety of indications.

The company develops transformative precision therapeutics to treat and cure disease by precisely controlling genomic expression for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases, and oncology. The company plans to advance OTX-2002, a possible therapy for hepatocellular carcinoma, as well as other next-generation pipeline assets, including its lead epigenomic controller candidate. Omega Therapeutics also plans to be listed on the Nasdaq under the symbol OMGA.